Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Share Price Should Tripple to Quadruple from now until ASCO

<< Previous

Bullboard Posts

Next >>

Post by SundayMovieson Apr 27, 2023 11:49am

207 Views

Post# 35417122

Share Price Should Tripple to Quadruple from now until ASCO

Similar to 2021 ASCO run, share Price Should Tripple to Quadruple from now until ASCO.

Not sure when the market will start doing this. Perhaps after Q1 on May 5th.

The news cycle is great/awesome.

You don't go to ASCO with a nothing burger. You show up ready, primed and with sexy data to wow the world.

I feel great about this stock now.

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects